Vis enkel innførsel

dc.contributor.authorLiposits, Gabor Isivan
dc.contributor.authorRyg, Jesper
dc.contributor.authorSkuladottir, Halla
dc.contributor.authorWinther, Stine B.
dc.contributor.authorMöller, Sören
dc.contributor.authorHofsli, Eva
dc.contributor.authorShah, Carl-Henrik
dc.contributor.authorPoulsen, Laurids Østergaard
dc.contributor.authorBerglund, Åke
dc.contributor.authorQvortrup, Camilla
dc.contributor.authorOsterlund, Pia
dc.contributor.authorGlimelius, Bengt
dc.contributor.authorSorbye, Halfdan
dc.contributor.authorPfeiffer, Per
dc.date.accessioned2023-03-01T10:09:05Z
dc.date.available2023-03-01T10:09:05Z
dc.date.created2022-12-24T12:45:23Z
dc.date.issued2023
dc.identifier.issn1879-4068
dc.identifier.urihttps://hdl.handle.net/11250/3054900
dc.description.abstractIntroduction Appropriate patient selection based on functional status is crucial when considering older adults for palliative chemotherapy. This pre-planned analysis of the randomized NORDIC9-study explored the prognostic value of four functional status measures regarding progression-free survival (PFS) and overall survival (OS) in vulnerable older patients with metastatic colorectal cancer (mCRC) receiving first-line palliative chemotherapy. Materials and methods Patients ≥70 years of age with mCRC not candidates for standard full-dose combination chemotherapy were randomized to receive full-dose S1 or reduced-dose S1 + oxaliplatin. At baseline, functional status was assessed using ECOG performance status (ECOG PS), frailty phenotype, Geriatric 8 (G8), and Vulnerable Elderly Survey-13 (VES-13). Multivariable regression models were applied and C-statistics were estimated. Results In total, 160 patients with a median age of 78 years (IQR: 76–81) were included. While in univariate analyses, ECOG PS, frailty phenotype, and VES-13 were statistically significantly associated with differences in OS between subgroups, G8 was not (HR = 1.55, 95%CI: 0.99–2.41, p = 0.050). In multivariable analyses adjusted for age, sex, body mass index, and treatment allocation, we found significant differences between subgroups for all applied tools and with C-statistics in the moderate range for ECOG PS and VES-13. Concerning PFS, statistically significant differences were observed between subgroups of ECOG PS, G8, and VES-13 both in uni- and multivariable analyses, but not for frailty phenotype. Discussion In this Nordic cohort of vulnerable older patients with mCRC, baseline ECOG PS, frailty phenotype, G8, and VES-13 showed prognostic value regarding overall survival, and moderate predictive value of models based on ECOG PS and VES-13 was demonstrated.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titlePrognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy – The randomized NORDIC9-studyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.articlenumber101408en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.jgo.2022.11.007
dc.identifier.cristin2097330
dc.source.journalJournal of Geriatric Oncologyen_US
dc.identifier.citationJournal of Geriatric Oncology. 2023, 14 (1), 101408.en_US
dc.source.volume14en_US
dc.source.issue1en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal